Abstract

Purpose: To study whether B7-H3 and B7-H4 proteins can be candidate drug targets for preventing and treating hepatoma.

Methods: Western blot assay was used to study the expressions of B7-H3 and B7-H4 proteins and the effect of sorafenib on their expressions in different human hepatoma cell lines (HepG2, Hep3B, BEL-7402, BEL-7404, BEL-7405, QGY-7701, QGY-7703, SMCC-7721, MHCC97H, MHCC97L, HCCLM3 and HCCLM6). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to study the cytotoxicity of sorafenib against different human hepatoma cell lines.

Results: The expressions of B7-H3 (0.26 - 0.84 μM) and B7-H4 (0.18 - 0.78 μM) proteins in different human hepatoma cell lines were significantly (p < 0.01) up-regulated, compared with that of the normal human liver cell line (HL-7702) (0.09 and 0.08 μM). Sorafenib was cytotoxic on Hep3B, BEL-7404, MHCC97H, HCCLM3 and HCCLM6 cells with half-maximal inhibitory concentration (IC50) of 14.56, 9.14, 9.46, 17.21 and 9.29 μM, respectively. After treatment with sorafenib at concentrations of 5, 10 and 20 μM, the expressions of B7-H3 protein in MHCC97H, HCCLM3 and HCCLM6 cells and the expressions of B7-H4 protein in Hep3B, BEL-7404 and MHCC97H cells were significantly (p < 0.01) down-regulated, compared with that of the control.

Conclusion: Over-expression of B7-H3 and B7-H4 proteins is common in different human hepatoma cell lines and thus, B7-H3 and B7-H4 proteins may be regarded as candidate drug targets for preventing and treating hepatoma.

Keywords: Hepatoma, B7-H3, B7-H4, Sorafenib, Over-expression, Cytotoxic activity, Down-regulation
radiation [7], chemotherapy [8], Chinese medicinal therapy [9] etc. The B7 protein family including B7-2, B7-1, B7-H4, B7-H3, B7-H2 and B7-H1 is a group of co-stimulators, which is related to the activation of T and B cells and immunologic functions. Therefore, the B7 protein family is widely applied to treat autoimmune diseases, transplantation immune diseases and cancers [10,11].

In the present study, western blot was used to study the expressions of B7-H3 and B7-H4 proteins in different human hepatoma cell lines (HepG2, Hep3B, BEL-7402, BEL-7404, BEL-7405, QGY-7701, QGY-7703, SMMC-7721, MHCC97H, MHCC97L, HCCLM3 and HCCLM6) and normal human liver cell line (HL-7702) [12]. Then 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to study the cytotoxicity of sorafenib against these cell lines (Hep3B, BEL-7404, MHCC97H, HCCLM3 and HCCLM6), which had the higher expressions of B7-H3 and B7-H4 proteins than other cell lines. Subsequently, the effects of sorafenib on the expressions of B7-H3 and B7-H4 proteins in Hep3B, BEL-7404, MHCC97H, HCCLM3 and HCCLM6 cells were studied using Western blot assays. The purpose was to determine whether the over-expressions of B7-H3 and B7-H4 proteins could be regarded as candidate drug targets for preventing and treating hepatoma.

**EXPERIMENTAL**

**Chemicals and reagents**

A defined fetal bovine serum, RPMI-1640 and DMEM medium were provided by Hyclone (Logan, Utah, USA) and Invitrogen (Carlsbad, CA, USA). Dimethylsulfoxide (DMSO), primary antibodies against β-actin, B7-H3, B7-H4 and horseradish peroxidase (HRP)-conjugated secondary antibody were purchased from Sigma-Aldrich (Taufkirchen, Germany). Sorafenib was purchased from LKT Laboratories (St Paul, Minnesota, USA). Enhanced BCA Protein Assay kit was obtained from Beyotime (Haimen, China).

**Cell culture**

The HepG2, Hep3B, BEL-7402, BEL-7404, BEL-7405, QGY-7701, QGY-7703, SMMC-7721, MHCC97H, MHCC97L, HCCLM3, HCCLM6 and HL-7702 cells were provided by American Type Culture Collection (ATCC, Manassas, VA, USA). All cells were separately cultured in RPMI-1640 or DMEM medium supplemented with 10 % defined fetal bovine serum, 100 U/mL of penicillin and 100 U/mL of streptomycin at 37 °C in 5 % CO2/95 % air.

**MTT assay**

MTT assay was used to evaluate the anti-proliferative activities of sorafenib against Hep3B, BEL-7404, MHCC97H, HCCLM3 and HCCLM6 cells. Different human hepatoma cells were separately seeded on 96 well plates for 24 h, and then cells were treated with sorafenib at the concentrations of 0 (for control), 1.25, 2.5, 5, 10, 15, 20 and 40 μM. After 48 h, the MTT was added into each well and the cells were cultured for another 3 h. Then the DMSO was added into each well and the optical density (OD) of the DMSO solution was measured at 570 nm using a microplate reader (Perkin-Elmer, USA) [13]. The inhibition rate of sorafenib against different human hepatoma cells were calculated as in Eq 1 [14].

\[
\text{Inhibition (\%)} = \left( \frac{\text{Ac} - \text{As}}{\text{Ac}} \right) \times 100 \quad \ldots \ldots \ldots (1)
\]

where Ac and As are the absorbance of control and sorafenib samples, respectively.

**Western blot assay**

The total proteins of untreated HepG2, Hep3B, BEL-7402, BEL-7404, BEL-7405, QGY-7701, QGY-7703, SMMC-7721, MHCC97H, MHCC97L, HCCLM3, HCCLM6 and HL-7702 cells were extracted. After treatment with sorafenib at concentrations of 0 (for control), 5, 10 and 20 μM for 48 h, the total proteins of Hep3B, BEL-7404, MHCC97H, HCCLM3 and HCCLM6 were extracted. According to the manufacturer's instruction, the concentrations of total proteins were determined using an Enhanced BCA Protein Assay kit [15]. Then, equal amounts of total proteins (about 30 μg) were separated by 12 % SDS/PAGE and moved onto PVDF membrane. After blocking with 5 % fat-free milk, the PVDF membranes were incubated with primary antibodies against β-actin, B7-H3, B7-H4 overnight at 4 °C and subsequently with goat anti-rabbit/HRP at room temperature for 2 h [16]. Finally, all proteins were detected by chemiluminescence. An antibody directed against β-actin was used to evaluate protein loading.

**Statistical analysis**

All data are presented as mean ± standard deviation. A one-way ANOVA was used to analyze the differences among different groups using Dunnett test on SPSS 19.0. When p-value...
was less than 0.05, the differences were recognized as statistically significant.

RESULTS

Over-expressions of B7-H3 and B7-H4 proteins

Western blot was used to study the expressions of B7-H3 and B7-H4 proteins in HepG2, Hep3B, BEL-7402, BEL-7404, BEL-7405, QGY-7701, QGY-7703, SMMC-7721, MHCC97H, MHCC97L, HCCLM3, HCCLM6 and HL-7702 cell lines. As shown in Figure 1, the expressions of B7-H3 (0.26 - 0.84 μM) and B7-H4 (0.18 - 0.78 μM) proteins in all the hepatoma cell lines were significantly (p < 0.01) up-regulated, compared with that of the normal human liver cell line (HL-7702) (0.09 and 0.08 μM).

Cytotoxicity of sorafenib against different human hepatoma cell lines

The cell lines (Hep3B, BEL-7404, MHCC97H, HCCLM3 and HCCLM6), which had the higher expressions of B7-H3 and B7-H4 proteins than other cell lines, were used to study the effect of sorafenib on the expressions of B7-H3 and B7-H4 proteins. However, before beginning the study, MTT assay was first used to determine the cytotoxicity of sorafenib against these cell lines to ensure the effectiveness of the drug. As depicted in Figure 2, sorafenib was cytotoxic to Hep3B, BEL-7404, MHCC97H, HCCLM3 and HCCLM6 with half maximal inhibitory concentration (IC50) values of 14.56, 9.14, 9.46, 17.21 and 9.29 μM, respectively.

Inhibitory effects of sorafenib on the expressions of B7-H3 and B7-H4 proteins

The effects of sorafenib on the expressions of B7-H3 protein in MHCC97H, HCCLM3 and HCCLM6 cells and the expressions of B7-H4 protein in Hep3B, BEL-7404 and MHCC97H cells were studied using western blot. As shown in Figure 3, after treatment with sorafenib at the concentrations of 5, 10 and 20 μM for 48 h, the expressions of B7-H3 protein in MHCC97H, HCCLM3 and HCCLM6 cells were significantly (p < 0.01) down-regulated, compared with that of the control. As shown in Figure 4, after treatment with sorafenib at the concentrations of 5, 10 and 20 μM for 48 h, the expressions of B7-H4 protein in Hep3B, BEL-7404 and MHCC97H cells were significantly (p < 0.01) down-regulated, compared with that of the control.

Figure 1: Over-expressions of B7-H3 and B7-H4 proteins in different human hepatoma cell lines (HepG2, Hep3B, BEL-7402, BEL-7404, BEL-7405, QGY-7701, QGY-7703, SMMC-7721, MHCC97H, MHCC97L, HCCLM3 and HCCLM6), **p < 0.01, compared with that of the normal human liver cell line (HL-7702)
Figure 2: Cytotoxicity of sorafenib against Hep3B, BEL-7404, MHCC97H, HCCLM3 and HCCLM6 cells

Figure 3: Inhibitory effects of sorafenib on the expressions of B7-H3 protein in MHCC97H, HCCLM3 and HCCLM6 cells, **p < 0.01, compared with that of the control

Figure 4: Inhibitory effects of sorafenib on the expressions of B7-H4 protein in Hep3B, BEL-7404 and MHCC97H cells, **p < 0.01, compared with that of the control

Trop J Pharm Res, October 2015; 14(10): 1800
DISCUSSION

In the present study, we studied the expressions of B7-H3 and B7-H4 proteins in different human hepatoma cell lines (HepG2, Hep3B, BEL-7402, BEL-7404, BEL-7405, QGY-7701, QGY-7703, SMMC-7721, MHCC97H, MHCC97L, HCCLM3 and HCCLM6) and normal human liver cell line (HL-7702) using western blot assay. Then, the cytotoxicity of sorafenib against Hep3B, BEL-7404, MHCC97H, HCCLM3 and HCCLM6 cells and the effect of sorafenib on the expressions of B7-H3 and B7-H4 proteins in these cells were studied using MTT and western blot assays.

Defect in the immune response may lead to the growth of tumor. T cell plays an important role in immune response. Co-stimulatory ligands such as CD80 and CD86 play an important role in the startup and maintenance of immune response, and their non-expressions in tumor cells has been regarded as a reason for immune evasion [17,18].

The expressions of inhibitory cofactors such as CD152 and PD-1 in immune cells, and the expression of their ligands in tumor cells are related to tumor pathogenesis [19]. Nowadays, inhibiting the interaction of inhibitory cofactors with their ligands has been successfully used to treat tumor [20]. Blocking the expressions of inhibitory cofactors in immune cells and the expressions of their ligands in tumor cells may be important in suppressing the immune evasion of tumor cells [21].

B7-H4 and B7-H3 are two major co-stimulators or ligands of inhibitory cofactors in B7 protein family, which is related to the activation of T cells and immunologic functions [22]. B7-H4 is expressed at the transcriptional level in the thymus, lung and spleen [23] while B7-H3 is widely expressed at the transcriptional level in lymphoid organs, liver, testis, uterus, lung, skeletal muscle, etc [24]. Therefore, B7-H4 and B7-H3 seem to be limited at the translational level [25]. It was reported that the B7-H4 and B7-H3 proteins were expressed in non-small-cell lung cancer [26].

Some studies indicate that B7-H4 is overexpressed at the transcriptional level in human hepatoma cell line BEL-7404 [27]. However, the expressions of B7-H3 and B7-H4 proteins in different human hepatoma and normal human liver cell lines and the effect of sorafenib on their expressions were still unknown. Because sorafenib can prevent both tumor cell proliferation and angiogenesis, and has been successfully used to treat hepatoma [28,29], it was considered as positive drug in the present study.

The results indicate that the expressions of B7-H3 and B7-H4 proteins in all the human hepatoma cell lines were significantly up-regulated, compared with that of the normal human liver cell line (HL-7702). Sorafenib was cytotoxic to Hep3B, BEL-7404, MHCC97H, HCCLM3 and HCCLM6 with IC50 values of 14.56, 9.14, 9.46, 17.21 and 9.29 μM, respectively.

After treatment with sorafenib, the expression of B7-H3 protein in MHCC97H, HCCLM3 and HCCLM6 cells and the expression of B7-H4 proteins in Hep3B, BEL-7404 and MHCC97H cells were significantly down-regulated, compared with that of the control. Although overexpression of B7-H3 and B7-H4 proteins was observed in the human hepatoma cell lines, expressions of B7-H3 and B7-H4 proteins in liver cancer tissues, the relationship between them, and the classification of liver cancer requires further study.

CONCLUSION

Over-expression of B7-H3 and B7-H4 proteins in human hepatoma cell lines are common. Sorafenib is cytotoxic to human hepatoma cell lines and inhibit t over-expression of B7-H3 and B7-H4 proteins in human hepatoma cell lines. These findings indicate that B7-H3 and B7-H4 proteins may be regarded as candidate drug targets for preventing and treating hepatoma.

REFERENCES

1. Lataro KJ, Demirjian AN, Pawlik TM. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am 2015; 24(1): 1-17.
2. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9: 191-211.
3. Ferlay J, Shin H, Bray F. GLOBOCAN 2008 v2.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. Lyon (France): International Agency for Research on Cancer; 2010.
4. Akoad ME, Pomfret EA. Surgical resection and liver transplantation for hepatocellular carcinoma. Clin Liver Dis 2015; 19(2): 381-399.
5. Xing SQ, Zhang CG, Yuan JF, Yang HM, Zhao SD, Zhang H. Adiponectin induces apoptosis in hepatocellular carcinoma through differential modulation of thioredoxin proteins. Biochem Pharmacol 2015; 93(2): 221-231.
6. Habib A, Desai K, Hickey R, Thornburg B, Lewandowski R, Salem R. Locoregional therapy of hepatocellular carcinoma. Clin Liver Dis 2015; 19(2): 401-420.

7. Yang DS, Yoon WS, Lee JA, Lee NK, Lee S, Kim HJ, Lee SH, Chung HH, Cha SH. The effectiveness of gadolinium MRI to improve target delineation for radiotherapy in hepatocellular carcinoma: a comparative study of rigid image registration techniques. Phys Medica 2014; 30(6): 676-681.

8. Chen YJ, Chen Y, Xiao D, Bose A, Deng RT, Bothun GD. Low-dose chemotherapy of hepatocellular carcinoma through triggered-release from bilayer-decorated magnetoliposomes. Colloid Surface B 2014; 116: 452-458.

9. Hu YY, Wang SP, Wu X, Zhang JM, Chen R, Chen MW, Wang YT. Chinese herbal medicine-derived compounds for cancer therapy: a focus on hepatocellular carcinoma. J Ethnopharmacol 2013; 149(3): 601-612.

10. Lei CX. B7 family-important co-stimulatory molecules. Immunol J 2002; 18(3): 54-57.

11. Salceda S, Tang T, Kmet M, Munteanu A, Ghosh M, Macina R, Liu WH, Pilkington G, Papkoff J. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res 2005; 306: 128-141.

12. Alexander JJ. Human hepatoma cell lines: Neoplasms of the Liver. Springer Japan; 1987: pp 47-56.

13. Li C, Chi S, He N, Zhang X, Guicherit O, Waqner R, Tyring S, Xie J. IFNalpha induces Fas expression and apoptosis in hedgehog pathway activated BCC cells through inhibiting Ras-Erk signaling. Oncogene 2004; 23(8): 1608-1617.

14. Li W, Li DY, Wang HD, Zheng ZJ, Hu J, Li ZZ. Juglans regia Hexane extract exert antitumor effect, apoptosis induction and cell circle arrest in prostate cancer cells in vitro. Trop J Pharm Res 2015; 14(3): 399-405.

15. Huang T, Long M, Huo B. Competitive binding to cuprous ions of protein and BCA in the biconichinonic acid protein assay. Open Biomed Eng J 2010; 4: 271-278.

16. Zi FM, He JS, Li Y, Wu C, Yang L, Yang Y, Wang LJ, He DH, Zhao Y, Wu WJ, et al. Metformin displays anti-myeoma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models. Cancer Lett 2015; 356: 443-453.

17. Subauste CS, Malefyt RW, Fuh F. Role of CD80 (B7.1) and CD86 (B7.2) in the immune response to an intracellular pathogen. J Immunol 1998; 160: 1831-1840.

18. Lumsden JM, Roberts JM, Harris NL, Peach RJ, Ronchese F. Differential requirement for CD80 and CD80/CD86-dependent costimulation in the lung immune response to an influenza virus infection. J Immunol 2000; 164(1): 79-85.

19. Leibson PJ. The regulation of lymphocyte activation by inhibitory receptor. Curr Opin Immunol 2004; 16(3): 328-336.

20. Hodi FS, Mihm MC, Solfer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Nati Acad Sci USA 2003; 100(8): 4712-4717.

21. Pardoll DM. The blockage of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12(4): 252-264.

22. Wang L, Liu LH, Shan BE. B7-H3: a promising target for tumor immunotherapy. Immunol J 2012; 28(8): 726-729.

23. Liu CZ, Yang KG, Cheng SS. B7-H4: a new negative regulator of T cell immunity. Chem Life 2009; 29(6): 794-798.

24. Sica GL, Choi IN, Zhu GF, Tamada K, Wang SD, Tamura H, Chapoval AI, Files DB, Bajorath J, Chen LP. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunology 2003; 18(6): 849-861.

25. Chapoval AI, Ni J, Lau JS, Wilcox RA, Files DB, Liu D, Dong H, Sica GL, Zhu G, Tamada K, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2001; 2(3): 269-274.

26. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005; 23: 515-548.

27. Sun YP, Wang YS, Zhao JQ, Gu M, Giscombe R, Lefvert AK, Wang XB. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 2006; 53(2): 143-151.

28. Du ZD, Yu JP, Xu XP, Lin WW, Xu L, Peng F. The expression of B7-H4 mRNA in HCC cell lines and the changes in BEL-7404 after using sorafenib. J Med Res 2011; 40(2): 30-33.

29. Bajetta E, Procopio G, Colombo A, Guadalupi V, Verzoni E, Pietrantonio F, Pusceddu S, Manzoni M, Gevorgyan A, Buzzoni R. Sorafenib in hepatocellular carcinoma. Clin Med Ther 2009; 1: 277-287.